Cytokinetics, Inc. (CYTK)
Q2 2012 Earnings Call
July 31, 2012, 4:30 p.m. ET
Sharon Barbari - EVP, Finance & CFO
Robert Blum - President & CEO
Andrew Wolff - SVP, Clinical Research and Development, & CMO
Fady I. Malik – SVP Research and Early Development
Ritu Baral – Canaccord Genuity
Charles Duncan - JMP Securities
Michael King – Rodman & Renshaw LLC
Simos Simeonidis – Cowen and Company
Chad Messer – Needham & Co.
George Zavoico – Mcnicoll, Lewis & Vlak
Good afternoon, and welcome Ladies and Gentlemen to the Cytokinets second quarter 2012 conference call. (Operator Instructions)
I will now turn the call over to Sharon Barbari, Cytokinets Executive Vice President of Finance and CFO. Please go ahead.
Good afternoon, and thank you for joining the Cytokinets senior management team on this conference call today. Also present during this call are Robert Blum, our President and Chief Executive Officer, Dr. Andrew Wolff, Senior Vice President of Clinical Research and Development and Chief Medical Officer, and Dr. Fady Malik, Senior Vice President of Research and Early Development.
Following the forward-looking statement disclaimer, Robert will provide a summary overview of the past quarter along with brief highlights on the advancement of clinical development pipeline including omecamtiv mecarbil and tirasemtiv, formerly referred to as CK2017357.
Andy will then provide details of recent progress in our skeletal muscle activator program directed to the potential treatment of ALS. And Fadi will provide details on recent progress in our cardiac muscle activator program directed to the potential treatment of heart failure.